HOME > RESOURCES > MEDICAL ARTICLES

Colorectal Cancer

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer deaths.

The risk of developing colorectal cancer is influenced by a variety of factors, including age, family history, personal medical history, lifestyle factors such as diet and exercise, and certain medical conditions such as inflammatory bowel disease.

Treatment for colorectal cancer depends on the stage of the disease and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. In general, the earlier the cancer is diagnosed and treated, the better the prognosis.

Surgery is the most common treatment for colorectal cancer and involves removing the tumor and any nearby lymph nodes. Radiation therapy uses high-energy radiation to kill cancer cells, while chemotherapy uses drugs to kill cancer cells or stop them from dividing.

Targeted therapy is a newer type of treatment that specifically targets certain molecules or pathways involved in the growth and spread of cancer cells. These treatments can be highly effective in some patients and are often used in combination with other treatments.

In recent years, there have been significant advances in the understanding of the biology of colorectal cancer, which has led to the development of new targeted therapies and immunotherapies. These treatments are more precise and have fewer side effects compared to traditional chemotherapy.

Colorectal cancer is a serious and potentially life-threatening disease, but with the right treatment, it can be managed effectively.

• • •

Natevba is a targeted therapy that works by inhibiting certain proteins that are involved in the growth and spread of cancer cells. This medication is specifically designed to target the underlying biology of colorectal cancer, which can improve outcomes and reduce the risk of recurrence.

Clinical trials have shown that Natevba can significantly improve progression-free survival in patients with advanced or metastatic colorectal cancer. Additionally, this medication has a favourable safety profile and is generally well-tolerated by patients.

At our company, we are committed to providing healthcare professionals with the latest information about Natevba and its use in the treatment of colorectal cancer. As such, we invite you to download our journal article on the treatment of colorectal cancer.

Prevalence of Pathogenic Germline Variants in Patients with Early-Onset Colorectal Cancer (CRC). The prevalence of pathogenic germline variants is shown for early-onset CRC (left) as compared with CRC in all age groups (right).